Long-term oral anticoagulants (OACs) and dual-antiplatelet therapy represent the recommended treatment in patients with atrial fibrillation and a high CHA 2 DS 2-VASc score, and in patients ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...
Results The management of antiplatelet and antithrombotic agents before, during, and after endovascular neurointerventional procedures continues to evolve. The following recommendations were agreed on ...
In simulated comparisons, the novel oral anticoagulants ranked better than VKA or antiplatelet therapies for prevention of stroke, ischaemic stroke or systemic embolism and mortality. Conclusions In ...
"The findings of the PUMICE randomized clinical trial indicate that thrombolysis with prourokinase did not demonstrate ...
Objectives Patients with SLE take multiple medications. Within a large prospective longitudinal SLE cohort, we characterised ...
Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ...
Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...
AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.
The severity of left ventricular diastolic dysfunction affects risk for incident stroke and transient ischemic attack, as well as major bleeding.